Table 2.
Effect of intensive SBP lowering on cardiovascular outcomes stratified by combined LVH and biomarker categories
| Outcome | Standard SBP Events/Total No. (%) | Intensive SBP Events/Total No. (%) | HR (95% CI) | P a | 4-year ARR (%) (95% CI) | NNT |
|---|---|---|---|---|---|---|
| Incident ADHF events and all-cause mortality | 0.68 | |||||
| LVH − biomarker − | 54/2193 (2.5%) | 28/2168 (1.3%) | 0.52 (0.33, 0.83) | 1.2% (0.0%, 2.5%) | 82 | |
| LVH − biomarker+ | 177/1843 (9.6%) | 133/1918 (6.9%) | 0.71 (0.57, 0.89) | 2.5% (−0.3%, 5.3%) | 41 | |
| LVH+ biomarker− | 8/128 (6.3%) | 6/121 (5.0%) | 0.77 (0.27, 2.23) | 2.0% (−6.6%, 10.7%) | 50 | |
| LVH+ biomarker+ | 37/238 (15.5%) | 24/211 (11.4%) | 0.70 (0.42, 1.16) | 4.4% (−5.2%, 13.9%) | 23 | |
| All-cause mortality | 0.88 | |||||
| LVH − biomarker − | 42/2193 (1.9%) | 27/2168 (1.2%) | 0.65 (0.40, 1.06) | 0.7% (−0.5%, 1.9%) | 143 | |
| LVH − biomarker+ | 126/1843 (6.8%) | 99/1918 (5.2%) | 0.75 (0.58, 0.98) | 1.6% (−0.8%, 4.0%) | 64 | |
| LVH+ biomarker− | 6/128 (4.7%) | 4/121 (3.3%) | 0.69 (0.19, 2.43) | 2.1% (−5.3%, 9.5%) | 49 | |
| LVH+ biomarker+ | 28/238 (11.8%) | 15/211 (7.1%) | 0.58 (0.31, 1.09) | 5.9% (−2.1%, 14.0%) | 17 |
Abbreviations: ADHF, acute decompensated heart failure; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
a
P-value for interaction on the relative hazard scale.